Promed Bioscience Ltd

Based in Cyprus, Promed Bioscience Ltd specializes in the development and production of advanced collagen-based biomaterials, aiming to enhance applications in the medical and cosmeceutical sectors. Promed Bioscience Ltd, founded in 2017 by co-founders Marianna Prokopi, Costas Pitsillides and Telemachos Hassapis is headquartered in Limassol, Cyprus, and operates primarily in the biotechnology field focusing on collagen-based solutions. In November 2025, Promed Bioscience Ltd raised EUR 1. 25 million in growth funding led by investor Kinisis Ventures.

Promed Bioscience specializes in the development and production of collagen-based biomaterials, focusing on highly purified medical-grade atelocollagen derived from animal tissue. Their core offerings include ultrapure atelocollagen extracted through proprietary enzymatic treatment, ensuring complete removal of degradation byproducts, enhancing biocompatibility and biodegradability. The products are tailored for applications across research, clinical, and cosmeceutical sectors, including collagen scaffolds and custom-made 3D structures for tissue engineering and cell adhesion. Promed Bioscience's revenue is primarily driven by direct sales of its collagen-based products to research institutions, healthcare facilities, and cosmeceutical firms.

Transactions occur through B2B agreements for bulk quantities of atelocollagen and related biomaterials, focusing on competitive pricing to maintain market appeal. Key products like ultrapure atelocollagen contribute significantly to the company's revenue generation in the biotechnology sector. The company will use the November 2025 funding to scale collagen biomaterial production, expand U. S.

commercial operations, accelerate international market entry, and strengthen R&D capabilities for advanced regenerative medicine solutions.